Skip to main content

Table 1 Patient and Treatment Characteristics

From: Hyperfractionated abdominal reirradiation for gastrointestinal malignancies

Characteristic

Median [IQR] or Number (%)

Age at 2nd Radiation Treatment (years)

65 [54.1–69.1]

Sex

 Male

16 (67%)

 Female

8 (33%)

Pathology of Initial Primary

 Pancreatic Adenocarcinoma

11 (46%)

 Upper GI Adenocarcinomaa

4 (16.7%)

 Colon Adenocarcinoma

3 (12.5%)

 Hepatobiliary Cancersb

4 (16.7%)

 Otherc

2 (8.3%)

Dose/fractionation of 1st Radiation Treatment (total dose in Gray (Gy)/total number of fractions)

 30Gy/24 fractions

1 (4.2%)

 30Gy/10 fractions

4 (16.7%)

 30Gy/12 fractions

1 (4.2%)

 35Gy/14 fractions

2 (8.3%)

 45Gy/25 fractions

8 (33.3%)

 50.4Gy/28 fractions

8 (33.3%)

Retreatment Interval (months)

27.9 [18.6–38.9]

Type of Post-1st Radiation Disease

 Recurrent Disease

21 (87.5%)

 Second Primary Tumor

3 (12.5%)

Location of Post-1st Radiation Disease

 Pancreas

14 (58.3%)

 Stomach/Duodenum

5 (20.8%)

 Liver

2 (8.3%)

 Otherd

3 (12.5%)

Reirradiation Intent

 Definitive/Local Control

16 (67%)

 Palliation of Bleeding

5 (20.8%)

 Palliation of Pain

2 (8.3%)

 Palliation of Tumor Thrombus

1 (4.2%)

Reirradiation Dosee (total dose in Gray (Gy)/total number of fractions)

 15Gy/10 fractions

1 (4.2%)

 30Gy/20 fractions

7 (29.2%)

 39Gy/26 fractions

15 (58.3%)

 45Gy/30 fractions

1 (4.2%)

Reirradiation Technique

 3D Conformal

15 (62.5%)

 Intensity-modulated radiation therapy

9 (37.5%)

Concurrent Chemotherapy

 Yes

17 (70.9%)

 No

7 (29.2%)

  1. IQR interquartile range
  2. aUpper GI Adenocarcinoma = adenocarcinomas of the gastroesophageal junction (N = 1), stomach (N = 1) and duodenum (N = 2)
  3. bHepatobiliary Cancers = intrahepatic cholangiocarcinoma (N = 2), extrahepatic cholangiocarcinoma (N = 1) and hepatocellular carcinoma (N = 1)
  4. cOther = pancreatic neuroendocrine tumor (N = 1), Hodgkin Lymphoma treated with mantle and abdominal fields (N = 1)
  5. dOther = Mesenteric adenopathy, peritoneal nodules, aortocaval adenopathy
  6. eReirradiation was given in twice daily fractions with a minimum 6 h interfraction interval